Drug-Eluting Balloon Versus Drug-Eluting Stent for Complex Femoropopliteal Arterial Lesions: The DRASTICO Study.

[1]  J. Beckman,et al.  Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices , 2019, JAMA cardiology.

[2]  D. Scheinert,et al.  Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease. , 2019, Journal of the American College of Cardiology.

[3]  L. Wann,et al.  ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and So , 2019, Journal of the American College of Cardiology.

[4]  S. Spiliopoulos,et al.  Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials , 2018, Journal of the American Heart Association.

[5]  Hong Wang,et al.  Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study Long Lesion Imaging Cohort , 2018, Circulation. Cardiovascular interventions.

[6]  M. Bacharach,et al.  A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial , 2018, The Lancet.

[7]  M. Taguri,et al.  Impact of Prolonged Inflation Times During Plain Balloon Angioplasty on Angiographic Dissection in Femoropopliteal Lesions , 2018, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[8]  S. Parikh,et al.  SCAI consensus guidelines for device selection in femoral‐popliteal arterial interventions , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  N. West,et al.  Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. , 2018, Journal of cardiology.

[10]  J. Hendriks,et al.  One-Year Outcomes of the Paclitaxel-Eluting, Self-Expanding Stentys Stent System in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia , 2017, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[11]  M. Shibuya,et al.  Biological effect on restenosis and vascular healing of encapsulated paclitaxel nanocrystals delivered via coated balloon technology in the familial hypercholesterolaemic swine model of in-stent restenosis. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  J. Reekers,et al.  A Decade of Drug-Eluting Technology in Peripheral Arterial Disease: Blurred by Dissembling Evidence , 2016, CardioVascular and Interventional Radiology.

[13]  F. Vermassen,et al.  Bioresorbable Everolimus-Eluting Vascular Scaffold for Patients With Peripheral Artery Disease (ESPRIT I): 2-Year Clinical and Imaging Results. , 2016, JACC. Cardiovascular interventions.

[14]  F. Castriota,et al.  1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study. , 2016, JACC. Cardiovascular interventions.

[15]  M. Böhm,et al.  Novel Sirolimus–Coated Balloon Catheter: In Vivo Evaluation in a Porcine Coronary Model , 2016, Circulation. Cardiovascular interventions.

[16]  M. Vardi,et al.  Variability in freedom from loss of primary patency results in trials assessing stent implantation in the superficial femoral artery. , 2014, The Journal of invasive cardiology.

[17]  M. Leesar,et al.  12‐month primary patency rates of contemporary endovascular device therapy for femoro‐popliteal occlusive disease in 6,024 patients: Beyond balloon angioplasty , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[18]  M. Leon,et al.  Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing , 2014, Open Heart.

[19]  I. Porto,et al.  Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). , 2013, JACC. Cardiovascular interventions.

[20]  P. Sidhu,et al.  Randomized Trial of the SMART Stent versus Balloon Angioplasty in Long Superficial Femoral Artery Lesions: The SUPER Study , 2013, CardioVascular and Interventional Radiology.

[21]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[22]  M. Nobuyoshi,et al.  Classification and clinical impact of restenosis after femoropopliteal stenting. , 2012, Journal of the American College of Cardiology.

[23]  M. Nobuyoshi,et al.  Long-term Outcomes and Risk Stratification of Patency Following Nitinol Stenting in the Femoropopliteal Segment: Retrospective Multicenter Analysis , 2011, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[24]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[25]  J. Beckman,et al.  Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. , 2008, Journal of vascular surgery.

[26]  Elazer R Edelman,et al.  Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Martin Schillinger,et al.  Long-Segment SFA Stenting—The Dark Sides: In-Stent Restenosis, Clinical Deterioration, and Stent Fractures , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[28]  Christopher Piorkowski,et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.

[29]  R. Hoyt,et al.  Peripheral arterial disease in people with diabetes: response to consensus statement. , 2004, Diabetes care.

[30]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[31]  Antonio Colombo,et al.  Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.

[32]  P. Greenland,et al.  Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery Disease , 1997, Journal of General Internal Medicine.

[33]  A Ross Naylor,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[34]  Peripheral Arterial Disease in People With Diabetes , 2003 .

[35]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.